We have located links that may give you full text access.
UVC Up-Conversion and Vis-NIR Luminescence Examined in SrO-CaO-MgO-SiO 2 Glasses Doped with Pr 3 .
Materials 2024 April 13
The application of ultraviolet-C light in the field of surface treatment or photodynamic therapy is highly prospective. In this regard, the stable fluorescent silicate SrO-CaO-MgO-SiO2 -Pr2 O3 glasses able to effectively convert visible excitation on the ultraviolet praseodymium emission were fabricated and examined. An unusual wide-range visible-to-UVC up-conversion within 240-410 nm has been achieved in Pr3+ -doped glasses, revealing their potential advantage in different sophisticated disinfection technologies. The integrated emission intensity was studied as a function of light excitation power to assess a mechanism attributed to UVC luminescence. Especially, it was revealed that the multicomponent silicate glass qualities and praseodymium 3 PJ excited state peculiarities are favorable to obtaining useful broadband ultraviolet up-converted luminescence. The glass dispersion qualities were determined between 450-2300 nm. The impact of praseodymium concentration on Vis-NIR spectroscopic glass qualities was evaluated employing absorption spectra, emission spectra, and decay curves of luminescence associated with two involved praseodymium excited states. Especially, efficient interionic interactions can be inferred by investigating the decrease in 1 D2 state experimental lifetime in the heavily doped samples. Examination of absorption spectra as a function of temperature implied that excitation at 445 nm should be quite effective up to T = 625 K. Contrary to this, temperature elevation gives rise to a moderate lowering of the visible praseodymium luminescence.
Full text links
Related Resources
Trending Papers
Guillain-Barré syndrome: History, pathogenesis, treatment, and future directions.European Journal of Neurology 2024 May 17
Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment.BMC Nephrology 2024 April 23
Angiotensin Receptor Blocker-Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction.Pharmacological Research : the Official Journal of the Italian Pharmacological Society 2024 May 12
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.Cardiac Failure Review 2024
European Respiratory Society Clinical Practice Guideline on symptom management for adults with serious respiratory illness.European Respiratory Journal 2024 May 9
Axillary Surgery for Breast Cancer in 2024.Cancers 2024 April 24
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app